Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Immuneering Corporation (NASDAQ:IMRX) has earned an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $16.50.

IMRX has been the topic of a number of analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immuneering in a research note on Monday, December 29th. Chardan Capital reaffirmed a “buy” rating and set a $20.00 price target on shares of Immuneering in a research report on Thursday, November 13th. Wall Street Zen cut shares of Immuneering from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Leerink Partners initiated coverage on shares of Immuneering in a research note on Friday, October 31st. They set an “outperform” rating and a $15.00 price objective on the stock. Finally, Mizuho set a $12.00 target price on shares of Immuneering in a research note on Wednesday, October 29th.

Immuneering Price Performance

Shares of NASDAQ IMRX opened at $4.63 on Friday. The business has a 50-day moving average of $5.99 and a 200-day moving average of $5.87. The stock has a market capitalization of $298.96 million, a price-to-earnings ratio of -2.60 and a beta of 0.48. Immuneering has a fifty-two week low of $1.10 and a fifty-two week high of $10.08.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.01). On average, sell-side analysts expect that Immuneering will post -1.86 EPS for the current year.

Insider Buying and Selling

In other Immuneering news, Director Peter Feinberg purchased 20,000 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The shares were acquired at an average price of $4.35 per share, for a total transaction of $87,000.00. Following the purchase, the director owned 135,441 shares in the company, valued at approximately $589,168.35. The trade was a 17.32% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Thomas J. Schall purchased 21,645 shares of the business’s stock in a transaction on Thursday, January 15th. The shares were acquired at an average cost of $4.67 per share, with a total value of $101,082.15. Following the acquisition, the director directly owned 74,530 shares in the company, valued at approximately $348,055.10. The trade was a 40.93% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders bought 51,819 shares of company stock valued at $234,472. Insiders own 22.90% of the company’s stock.

Hedge Funds Weigh In On Immuneering

Large investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its stake in shares of Immuneering by 2.0% during the 2nd quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock worth $776,000 after buying an additional 4,458 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Immuneering in the 3rd quarter valued at about $35,000. Future Financial Wealth Managment LLC acquired a new stake in Immuneering during the third quarter worth approximately $35,000. Dimensional Fund Advisors LP lifted its position in Immuneering by 46.4% during the third quarter. Dimensional Fund Advisors LP now owns 19,562 shares of the company’s stock worth $137,000 after acquiring an additional 6,196 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV bought a new stake in shares of Immuneering during the third quarter worth approximately $70,000. 67.65% of the stock is owned by institutional investors.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.